Pharmaxis Grants Aptar Pharma Exclusive Option to Develop and Promote High Payload Dry Powder Inhaler
17th
Aug 21
Release Date: 17/08/2021 8:30am
- Drug delivery solutions developer Aptar Pharma acquires an exclusive 12-month option for a worldwide license to the “Orbital” technology for $US2.5m plus sales royalties
- Pharmaxis receives a US$250k upfront fee for the option grant
- Orbital dry powder respiratory inhaler developed by Pharmaxis delivers large payloads of drug in a convenient easy-to-use format
- Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler
Categories: News and Media